Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.

Autor: Naguib GG; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt. Electronic address: Gina_gamal@med.asu.edu.eg., Farid A; Department of Tropical Medicine and Infectious Disease, Ain Shams University, Cairo, Egypt., Hassan M; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt; Armed Forces College of Medicine, Egypt., Elshafie A; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt; Armed Forces College of Medicine, Egypt., Shazly YE; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt., Shaker MK; Department of Tropical Medicine and Infectious Disease, Ain Shams University, Cairo, Egypt., Ezzat H; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt., Safwat E; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt., Ahmed OA; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Ain Shams University, Cairo, Egypt., Dabbous H; Department of Tropical Medicine and Infectious Disease, Ain Shams University, Cairo, Egypt., Sherief AF; Department of Tropical Medicine and Infectious Disease, Ain Shams University, Cairo, Egypt., Hassany M; National Hepatology & Tropical Medicine Research Institute, Dept Trop Med, Cairo, Egypt., Elserafy M; Department of Tropical Medicine, Faculty of Medicine, Cairo University, Egypt., Elsayed MH; Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Egypt.
Jazyk: angličtina
Zdroj: Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology [Arab J Gastroenterol] 2021 Dec; Vol. 22 (4), pp. 285-291. Date of Electronic Publication: 2021 Sep 13.
DOI: 10.1016/j.ajg.2021.06.001
Abstrakt: Background and Study Aims: Chronic hepatitis C virus (HCV) infection has always been identified as a major health threat and a potential cause of liver cirrhosis, portal hypertension, and other associated problems. The introduction of direct-acting antiviral agents (DAAs) has represented a paradigm shift in HCV management. In this study, we aim to observe the rate of sustained virologic response (SVR12) in a large scale of patients at a single center as well as record the post-treatment changes in the hematologic, hepatic, and renal biochemical profiles.
Patients and Methods: In total, 1933 chronic HCV genotype 4 mono-infected non-HCC patients who completed the treatment with six different DAA regimens in the Faculty of Medicine, Ain Shams University Research Institute (MASRI), were retrospectively enrolled in this study. The rate of sustained virologic response after 12 weeks off-therapy (SVR12) was assessed. The baseline characteristics to predict the SVR12 were then analyzed. The post-treatment changes in many profiles were recorded and analyzed.
Results: The overall SVR12 rate was 96.2% (after excluding 84 cases who were lost to follow-up). It was achieved in 346/375 patients (92.3%), 466/477 patients (97.7%), 60/62 patients (96.8%), 11/11 patients (100%), 532/545 patients (97.6%), and 445/463 patients (96.1%) who received sofosbuvir/daclatasvir (SOF/DCV), sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV), sofosbuvir/ledipasvir (SOF/LDV), sofosbuvir/ledipasvir/ribavirin (SOF/LDV/RBV), sofosbuvir/simeprevir (SOF/SMV), and ombitasvir/paritaprevir/ritonavir/ribavirin (OBV/PTV/r + RBV), respectively. In total, 73 patients (3.8%) failed to achieve SVR12. The baseline aspartate aminotransferase (AST), cirrhotic status, and treatment regimen were determined to have a significant impact on SVR12. In the overall treated population, the levels of serum AST, alanine aminotransferase, albumin, creatinine, bilirubin, and hemoglobin and platelet count improved significantly after treatment. Furthermore, sustained virologic response was strongly related to cirrhosis and its degree.
Conclusion: The interferon-free DAA regimens offered high SVR12 rates in Egyptian patients with chronic HCV infection. They were associated with a significant improvement in the hematologic, hepatic, and renal biochemical profiles. The baseline AST, liver cirrhosis, and treatment regimen might have an impact on achieving SVR.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: